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REVIEWARTICLE
Diabetic Nephropathy: a Tangled Web to Unweave
Corey Magee1 & David J. Grieve1 & Chris J. Watson1 & Derek P. Brazil1
# The Author(s) 2017. This article is an open access publication
Abstract Diabetic nephropathy (DN) is currently the leading
cause of end-stage renal disease globally. Given the increasing
incidence of diabetes, many experts hold the view that DN
will eventually progress toward pandemic proportions.
Whilst hyperglycaemia-induced vascular dysfunction is the
primary initiating mechanism in DN, its progression is also
driven by a heterogeneous set of pathological mechanisms,
including oxidative stress, inflammation and fibrosis.
Current treatment strategies for DN are targeted against the
fundamental dysregulation of glycaemia and hypertension.
Unfortunately, these standards of care can delay but do not
prevent disease progression or the significant emotional, phys-
ical and financial costs associated with this disease. As such,
there is a pressing need to develop novel therapeutics that are
both effective and safe. Set against the genomic era, numerous
potential target pathways in DN have been identified.
However, the clinical translation of basic DN research has
been met with a number of challenges. Moreover, the notion
of DN as a purely vascular disease is outdated and it has
become clear that DN is a multi-dimensional, multi-cellular
condition. The review will highlight the current therapeutic
approaches for DN and provide an insight into how the inher-
ent complexity of DN is shaping the research pathways to-
ward the development and clinical translation of novel thera-
peutic strategies.
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Introduction
Diabetes mellitus (DM) is a systemic disease that is
characterised by an inability of the body to either produce or
effectively respond to the glucose-regulating hormone, insulin
[1]. Type 1 DM results from an idiopathic autoimmune de-
struction of pancreatic β-cells, whilst widespread peripheral
insulin resistance drives type 2 DM [1]. The resulting
hyperglycaemia upsets haemodynamic and metabolic homeo-
stases, whilst the chronic nature of this microenvironmental
disequilibrium promotes the development of diffuse cellular
abnormalities. As a result, many patients develop serious com-
plications, the most devastating of which is extensive vascular
dysfunction [2]. Given that the kidneys are highly sensitive to
both haemodynamic and metabolic alterations, these organs
are vulnerable targets within the diabetic milieu. Diabetic ne-
phropathy (DN) is a key microvascular complication of DM.
DN is characterised by albuminuria (urinary albumin to creat-
inine ratio ≥ 30 mg/g) and an eventual decline in the estimated
glomerular filtration rate (eGFR < 60 ml/min/1.73 m2) [3].
DN follows distinct phases, where glomerular hyperfiltration
is followed by a relentless decline in renal function, typically
occurring over a 15–20 year period.
Currently, DN is the leading cause of end-stage renal dis-
ease (ESRD) globally [3]. Whilst the natural history of DN
can vary slightly, patients often experience a chronic condition
where progressive structural changes in the kidney correlate
with various stages of clinical renal deterioration. The devel-
opment of ESRD requires the use of dialysis or renal trans-
plantation, both of which can be associated with excess
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morbidity and mortality [4, 5]. Moreover, DN incidence rates
show no signs of slowing. In the USA alone, 42% of all ESRD
cases had a diagnosis of DN [6]. The importance of maintain-
ing optimal renal function is further evidenced by the fact that
DN is responsible for the vast proportion of excess mortality
risk in patients with DM [7, 8]. Thus, there is a clear unmet
need to develop novel DN-targeted therapeutics that can cur-
tail the unrelenting progression of this disease and, hence,
improve both the quality and quantity of life for this patient
group. This review will highlight the key molecular mecha-
nisms that drive DN whilst stressing the need to view DN as
more than a simple vascular complication. More importantly,
it will provide a critical insight into a range of exciting new
DN treatment strategies that are on the horizon.
Diabetic Nephropathy Pathogenesis
Metabolic and Haemodynamic Dysregulations
DN pathogenesis is characterised by a complex interplay be-
tween metabolic and haemodynamic disruptions [9]. In DN,
hyperglycaemia-induced metabolic impairment is central to
the development and progression of DN (Fig. 1) and, hence,
the appearance of defining renal lesions [10]. These include
glomerular basement membrane thickening, mesangial expan-
sion and the appearance of characteristic Kimmelstein-Wilson
nodules. These changes occur secondary to hyperglycaemia-
induced oxidative stress and accumulation of advanced
glycation end products. Additional critical mediators of DN
include haemodynamic elements, such as activation of vaso-
active hormonal pathways, most commonly the renin-
angiotensin-aldosterone system (RAAS). The associated sys-
temic hypertension contributes to increased intra-glomerular
pressure [8]. Glomerular microvascular lesions develop sec-
ondary to altered blood flow and increased vascular perme-
ability. The underlying signalling pathways involved are high-
ly complex, and current research is intensively focused on a
range of key molecular drivers.
Central to aberrant signalling in DN is the transforming
growth factor-beta 1 (TGF-β1), which has long been
recognised as a key driver of DN [11]. TGF-β1 expression is
elevated within various constituent kidney cells in DN [12,
13]. Dysfunctional TGF-β1 signalling modulates glucose flux
into renal cells by upregulating the glucose transporter,
GLUT-1 [10]. In effect, TGF-β1 is at the centre of a complex
signalling cascade-driving DN [14]. SMAD proteins are the
intra-cellular signalling effectors of TGF-β1 secondary to their
ability to translocate to the nucleus and regulate transcription
[15]. Animal models have highlighted the importance of the
TGF-β/SMAD pathway in the development of diabetic
glomerulosclerosis and tubulointerstitial fibrosis [16, 17].
Beyond this canonical pathway, recent studies have proven
the existence of complex crosstalk between TGF-β and other
well-known SMAD-independent pathways, such as Src proto-
oncogene non-receptor tyrosine kinase (Src) signalling.
Moreover, this redox-driven crosstalk has been shown to up-
regulate pro-fibrotic markers [18] and may provide new op-
portunities for targeted intervention.
Aside from the TGF-β pathway, a host of newly implicated
genes has been identified, due in part to the upsurge in
genome-wide association studies (GWAS). These have prov-
en to be powerful tools for defining the genetic architecture of
DN in patients. However, limitations of the genome-wide ap-
proach were recently exemplified by the GENIE consortium
[19]. Despite being the largest DN-focused GWAS to date,
this study highlighted the vast complexity underlying DN her-
itability. It is also important to realise that many newly
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identified genes likely only account for a limited proportion of
the observed phenotypic alterations in patients. Furthermore,
it is possible that the pathogenic pathways differ between type
1- and type 2-associated DN. Additionally, there is a distinct
likelihood that unique mechanisms promote disease initiation
versus disease progression.
Given that metabolic and haemodynamic changes are cen-
tral pathogenic drivers of DN, approaches to target these
mechanisms have become standards of care. However, it has
become clear that the management of hypertension [20] and
the pursuit of tight glycaemic control [21] are ineffective in
stopping the inevitable renal deterioration in many patients.
As a result, researchers are continuing to advance the under-
standing of DN, and as such, a wealth of novel therapeutic
targets are being identified. Such developments will be essen-
tial to facilitate more effective diagnosis and treatment of DN.
Diabetic Nephropathy: a Multi-cellular Affair
By virtue of the complex anatomical structure and intricate
physiology of normal kidneys, the intrinsic pathological fea-
tures of DN involve a multitude of constituent renal cells. As
highlighted previously, aberrant cellular signalling promotes
characteristic histological changes within diabetic kidneys via
the release of numerous secreted factors [22]. When
attempting to rank dysfunction of specific cellular types, DN
has often been viewed as a ‘podocentric’ disease, where the
highly specialised podocytes are often described as the
‘weakest link’ among the renal cell population [22].
However, glomerular endothelial cells (GEnCs) and
tubulointerstitial cells are increasingly implicated in the devel-
opment and progression of DN [23–26].
A common feature of diabetic cardiovascular compli-
cations is diffuse endothelial injury, and DN is no excep-
tion. GEnCs are continuous, highly fenestrated cells that
are covered by a thick glycoprotein layer of glycocalyx. It
has been demonstrated that altered permeability of the
GEnC layer can exacerbate levels of albuminuria, inde-
pendent of ultrastructural changes in the podocytes [27].
Interestingly, in a study by Qi et al. which compared the
transcriptomes of DN-resistant mice versus DN-
susceptible mice, there was a significant downregulation
of mitochondrial gene expression in the GEnCs of diabet-
ic mice, which was associated with an increase in mito-
chondrial DNA lesions [24]. These results were confirmed
using human tissue samples, where the authors correlated
their findings with rapidly progressing DN [24]. These
data provide new insights into the complexity of GEnC
pathology in DN and align with the unifying concept that
oxidative stress is central to diabetic vascular disease.
The myofibroblast represents another principal mediator of
DN. These mesenchymal cells promote extracellular matrix
accumulation and, hence, correlate positively with the amount
of renal fibrosis. Whilst their role in disease progression has
been firmly established, their origin remains controversial
[28]. One explanation that has gained attention centres on
the process of epithelial-to-mesenchymal transition (EMT).
During EMT, renal epithelial cells undergo phenotypic chang-
es, involving loss of epithelial markers and increased expres-
sion of mesenchymal genes [29]. Indeed, immunofluores-
cence has confirmed the presence of cells that stained positive
for α-smooth muscle actin (α-SMA), a smooth muscle differ-
entiation marker expressed by myofibroblasts, in renal inter-
stitial tissue originating from type 2 DM patients [30]. Such
findings directly contrast with work published by Humphreys
et al. who implemented Cre/Lox techniques to genetically
label renal epithelial cells in a mouse model of renal fibrosis
[31]. By using either β-galactosidase or red fluorescent pro-
tein as markers to track the fate of renal epithelial cells in vivo,
Humpheys et al. found no evidence to support the interstitial
migration of epithelial cells, highlighting a notable lack of α-
SMA-positive tubular cells [31]. This group suggested that the
myofibroblast arises from the vascular pericyte and, hence,
that therapeutic strategies against fibrotic kidney disease
should target pericyte differentiation [31].
Recent papers from the Nieto and Kalluri groups have
demonstrated a key role for the Snail transcription factor
in kidney fibrosis and suggest that epithelial cells undergo
a ‘partial’ EMT without continuing to the myofibroblast
population [32, 33]. By the same token, the role of an
analogous process called endothelial-to-mesenchymal
transition (EndoMT) in DN is beginning to become clear.
Evidence by Li et al. demonstrated the existence of this
phenomenon in streptozotocin (STZ)-induced diabetic
mice, a type 1 diabetic model [34], whilst a 2017 paper
by Shang et al. extended this process to human samples
by showing that nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) promotes EndoMT
in DN biopsy tissue contributing to renal fibrosis [35].
Furthermore, recent publications have highlighted a novel
role for bone marrow-derived myofibroblasts in renal fi-
brosis showing that pro-inflammatory macrophages are a
source of collagen-producing myofibroblasts in both ex-
perimental and human models of DN [36, 37].
Consideration of any cell type in isolation is limited, as
interactions between these cells are essential under both phys-
iological and pathological conditions. In this way, there is a
continuous bidirectional crosstalk that involves the exchange
of numerous cytokines and growth factors.Moreover, the phe-
notypic and functional heterogeneities among renal cells, in
particular renal endothelial cells, could imply the involvement
of numerous unique signalling pathways. As such, it is now
clear that the pathophysiology underpinning DN is a complex
multi-molecular, multi-cellular process and therefore,
targeting therapeutic strategies around more than one of these
pathological targets may be a sensible approach.
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Epigenetics: the Missing Piece of the Puzzle?
For years, researchers have focused on the pivotal role of
hyperglycaemia in the development of diabetic vascular com-
plications. However, it is known that DN can develop even in
those patients who show optimal blood glucose control [38,
39]. Moreover, the decline in renal function among DN pa-
tients is highly variable. In this regard, epigenetics is emerging
as a next-generational paradigm to characterise DN.
Epigenetics refers to the regulation of gene expression and
phenotype that occurs without the need for DNA sequence
changes. In keeping with the multi-factorial aetiology of
DM, it is clear that environmental factors and health behav-
iours influence disease pathology by inducing changes in epi-
genetically regulated mechanisms in chromatin, including
DNA methylation and histone post-translational modifica-
tions [40].
DNA methylation involves a methyl group being added to
the fifth carbon position of cytosine [41], and as a result, this
process inversely regulates gene expression. DNA methyla-
tion is an important modification in the context of complex
diseases. Altered DNA methylation profiles were detected in
DN [42, 43], and such investigations have documented differ-
ential methylation of various mediators of glomerular cell ap-
optosis [41]. Furthermore, genome-wide methylation screen-
ing has identified genes that are selectively hypermethylated
in fibrotic fibroblasts and thus, DNA methylation has been
strongly implicated in fibroblast-induced renal fibrosis [44].
Bechtel et al. highlighted that DNA methylation changes reg-
ulate the actions of TGF-β1 and that hypermethylation of RAS
protein activator like 1 (RASAL1) correlated strongly with
renal fibrogenesis [44].
Another compelling field of research is the role of non-
coding RNAs (ncRNAs) in DN pathogenesis. Despite their
appeal as novel biomarkers, the function of ncRNAs, such
as microRNAs, is somewhat perplexing. This is evidenced
by investigations into the role of mir-192, which demonstrated
both pro- and anti-fibrotic capabilities [45, 46]. Also, it is
important to realise that microRNAs rarely act in isolation.
This fact was nicely highlighted by a report that TGF-β1 in-
directly regulated endoplasmic reticulum stress in diabetic
mice, via targeting a mega-cluster of around 40 microRNAs
[47]. The role of long non-coding RNAs (lncRNAs) in DN is
now beginning to emerge. LncRNAs are ≥ 200 nucleotides in
length and function by means other than coding for proteins.
As such, plasmacytoma variant translocation 1 (PVT1) was
associated with diabetic ESRD in both type 1 and type 2 DM
[48]. Further work highlighted that PVT1 expression was up-
regulated by hyperglycaemia and that knockdown of this
lncRNA reduced the levels of key extracellular matrix pro-
teins in humanmesangial cells [49]. RNA sequencing analysis
of renal glomeruli identified differential expression of the
lncRNA, taurine upregulated 1 (Tug1) in the diabetic milieu
[50]. Recently, Li et al. showed that DN-associated upregula-
tion of metastasis-associated lung adenocarcinoma transcript
1 (MALAT1) expression promoted renal tubular epithelial
pyroptosis, an inflammatory form of programmed cell death,
by amplifying the inflammatory response via modulation of
ELAV-like RNA-binding protein 1 (EVAL1) signalling [51].
In the field of non-coding RNAs, it is expected that future
work will uncover a plethora of targets associated with DN.
Histone deactylation is another component of epigenetic
regulation, which converts permissive euchromatin to repres-
sive heterochromatin and, hence, causes transcriptional silenc-
ing. Histone deacetylases (HDACs) have garnered recent at-
tention due to their ability to effectively regulate the transcrip-
tional network. Despite relatively few publications, it is likely
that HDACs regulate key signalling events within the diabetic
kidney. Evidence to support this hypothesis has been provided
by both in vitro and in vivo research: For example, Noh et al.
showed that HDAC-2 could promote extracellular matrix ac-
cumulation in both renal tubular epithelial cells and renal tis-
sue of STZ-induced diabetic mice [52]. Increased expression
of HDAC-2/4/5 was documented in renal tissues of diabetic
animals and biopsy material from diabetic patients [53]. In
particular, HDAC-4 was found to selectively exacerbate
podocyte damage in DN [53].
Aside from histone modification, HDACs may regulate
non-histone proteins. HDACs have thus been highlighted as
potential regulators of pro-inflammatory gene expression in
DM [54]. The ability of HDACs to interact with the innate
and adaptive immune responses implicates these molecules in
the inflammatory pathogenesis of the diabetic kidney. In par-
ticular, NLR family pyrin domain-containing 3 (NLRP3) and
other inflammasome components act to trigger the inflamma-
tory cascade in the diabetic kidney [55]. In keeping with this,
activation of caspase-1 has been shown to downregulate
sirtuin 1 [56], a class III HDAC that usually engages in anti-
oxidative and anti-inflammatory functions. In fact, sirtuin 1
downregulation leads to endothelial dysfunction in DM [57].
Altered HDAC function may therefore contribute to a wide
range of pathological processes in DN. In contrast, HDAC-6
has been shown to negatively regulate NLRP3 activation [58]
and thus, therapeutic modulation of HDACs may emerge as a
useful therapeutic approach in DN. Although the precise roles
of HDACs remain poorly understood, their ability to regulate
both histone and non-histone proteins suggests that future re-
search will unearth pivotal roles in DN pathology.
To move a step further, it is now becoming clear that these
epigenetic capabilities confer ‘memory’ onto the cells. This
phenomenon of ‘metabolic memory’ or more specifically
‘hyperglycaemic memory’ is common to both macro- and
microvascular diabetic complications. In essence, this means
that even transient periods of suboptimal glucose control can
result in long-lasting consequences. This was evidenced in
numerous models by the persistence of oxidative stress [59]
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and a failure to resolve glomerular basement membrane thick-
ening [60] following blood glucose normalisation. It appears
that these cells may become imprinted with epigenetic marks
that are difficult, if not impossible, to reverse.
Even though the details of this complex process remain
elusive, research has uncovered some important contributors.
In this regard, it was suggested that prolonged epigenetic
changes, as well as the long-term accumulation of advanced
glycation end products, are compatible with this concept [61].
Furthermore, Geraldes et al. recently identified a novel marker
of podocyte-specific memory [62]. Having previously dem-
onstrated increased expression of the protein tyrosine phos-
phatase, SHP-1, in the renal cortex of type 1 diabetic mice, this
group subsequently showed that this molecule remained ele-
vated in podocytes even after systemic glucose normalisation
[62]. When considering the vast amount of published data,
there can be no doubt that the diabetic microenvironment in-
duces profound epigenetic changes and, hence, alters the fine
balance between beneficial and pathogenic transcriptome reg-
ulators. Furthermore, the ability to modulate metabolic mem-
ory may represent a powerful tool for the treatment of DN and
other diseases. By exploring the relatively uncharted epigenet-
ic landscape, researchers may uncover important insights into
the molecular basis of DN.
Current Standards of Care
Controlling Blood Glucose: the Holy Grail
For years, effective glycaemic control has been hailed as the
principal approach for reducing the incidence of diabetic com-
plications. In the setting of DN, the benefits of tight glucose
control were highlighted by examining the effects of sustained
normoglycaemia following pancreatic transplantation.
Fioretto et al. observed a reversal of renal lesions in DN pa-
tients after 10 years of normoglycaemia [63]. These landmark
results suggested that precisely controlled glucose levels had
the potential to promote significant reverse remodelling within
the diabetic kidney. A number of authoritative studies have
continued to support such benefits, including the Diabetes
Control and Complications Trial (DCCT) [64]. In its type 1
DM cohort, one DCCT demonstrated that intensive glucose
control improved various surrogate end points, including
macroalbuminuria [64]. Additionally, the follow-up stage
Epidemiology of Diabetes Interventions and Complications
(EDIC) trial identified long-lasting risk reductions among
the intensive therapy arm even when tight glucose control
was no longer in place [65]. Further encouraging results came
from the United Kingdom Prospective Diabetes Study
(UKPDS) where intensive glycaemic control achieved an
11% reduction in glycosylated haemoglobin (HbA1c), a
marker of glycaemic control in established DM, as well as a
33% decrease in microalbuminuria levels when compared to
conventional therapy at a median follow-up of 10 years [66].
Such results were replicated by the ADVANCE (Action in
Diabetes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation) trial, which ob-
served a notable 65% risk reduction for ESRD in the inten-
sivelymanaged arm of the study [67]. These findings have far-
reaching ramifications, as reductions in renal disease indices
should presumably associate with a reduced overall cardiovas-
cular risk profile. However, whilst albuminuria is a well-
established hallmark of DN, its sensitivity is somewhat limit-
ed. In this way, daily intra-patient fluctuations can confound
its analysis. The ACCORD (Action to Control Cardiovascular
Risk in Diabetes) trial also identified discordance between
albuminuria and eGFR [68]. The ACCORD trial further raised
concerns regarding strict glycaemic management by
highlighting excessive mortality in the intensive therapy arm
[68]. In a similar manner, analyses from the ADVANCE trial
identified an association between hypoglycaemia and the de-
velopment of adverse clinical effects [67]. These findings
highlight the difficulties of pursuing an intensive regimen in
diabetic patients. Considering the evidence supporting the
central position of hyperglycaemia in the development of di-
abetic vascular complications, it seems likely that clinicians
will continue to encourage their patients to aim for steady
improvements in glycaemic control to reduce the risk of dia-
betic complications, such as DN.
RAAS Inhibition: an Old Favourite
Themanagement of hypertension in DN is considered to be an
important component in the clinical management of patients.
Evidence for this was seen in the UKPDS trial where de-
creases in systolic blood pressure were associated with a de-
creased incidence of diabetic complications [66]. Inhibitors of
the RAAS, including angiotensin-converting enzyme inhibi-
tors (ACE-I) and angiotensin receptor blockers (ARB), are
currently the first-line therapies for DN [69]. The positive
effects of ARBs were highlighted by the RENAAL
(Reduction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan) [70] and IRMA-2 (Irbesartan in Patients
with Type 2 Diabetes and Microalbuminuria) [71] trials.
Moreover, the DETAIL (Diabetics Exposed to Telmisartan
and Enalapril) trial confirmed the consensus that both ACE-
Is and ARBs have equal efficacy in DN [72]. It is accepted that
these agents provide benefits beyond mere blood pressure
control, as evidenced by reductions in microalbuminuria
[73]. By reducing intra-glomerular pressure, ACE-Is and
ARBs have long-term effects on renal function even after
cessation, suggesting that these anti-hypertensive drugs nor-
malise some aspects of DN pathology [70]. Whilst these
agents were initially used in all DN patients, recent guidelines
recommend limiting their prescription to patients with
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proteinuria > 300 mg/day [74]. Despite representing the cur-
rent treatment of choice, these drugs merely slow DN progres-
sion. Additionally, traditional approaches to inhibit RAAS are
limited by an increased risk of hyperkalaemia in patients with
advanced disease. As such, there has been a concerted effort to
optimise RAAS inhibition, whilst limiting conceivable ad-
verse effects.
Recently, researchers questioned whether or not dual
RAAS blockade could provide additional nephroprotective
effects. In the ONTARGET (Ongoing Telmisartan Along
and in Combination with Ramipril Global Endpoint Trial)
study, combining the ARB, telmisartan, with the ACE-I,
ramipril, did not improve proteinuria levels and, more impor-
tantly, was associated with increased rates of hyperkalaemia
[75]. Similarly, the VA NEPHRON-D (Veterans Affairs
Nephropathy in Diabetes) trial destroyed any hopes for dual
blockade with an ACE-I and an ARB by confirming that this
approach offered no significant benefit in the primary end-
points of renal disease progression or death [76]. In fact, the
trial documented increased risks of serious adverse effects,
including hyperkalaemia and acute kidney injury [76].
Despite considerable evidence that dual blockade should be
avoided due to adverse side effects, there is an indication that
an increasing proportion of patients is being managed in this
way [77]. However, a recent glimmer of hope emerged fol-
lowing the development of novel potassium-binding drugs,
including the oral non-absorbed polymer, patiromer. When
used in combination with RAAS inhibition, only 15% of stage
3/4 CKD patients developed hyperkalaemia compared to 60%
among the placebo group [78]. Direct renin inhibition was
considered as another approach to optimise RAAS modula-
tion. Initial results from the AVOID trial were promising, as
the addition of a direct renin inhibitor, aliskiren, to losartan
therapy resulted in a 20% reduction in the urinary albumin to
creatinine ratio [79]. However, in a similar manner to dual
RAAS blockade, the larger ALTITUDE study was terminated
after 2.7 years due to the absence of change in renal outcomes
and excess adverse effect risk in the aliskiren arm of the trial
[80]. As it stands, clinicians are currently limited to prescrib-
ing only one RAAS-targeting agent for DN patients. Taken
together, it seems that conventional RAAS blockade is
reaching its limits in terms of DN patient benefit.
Novel Therapeutic Approaches
Anti-diabetic Drugs: Unanticipated Benefits
Whilst researchers are often driven to develop new targets and
novel therapies, an important part of medicine involves
recognising when the solution is already within our grasp.
As such, a number of currently available anti-diabetic drugs
have shown promise in the treatment of DN. One particularly
promising group is the sodium-glucose cotransporter-2
(SGLT2) inhibitors, such as empagliflozin. Beyond blood glu-
cose control, these drugs possess potent renoprotective effects.
A recent study by Wang et al. observed increased SGLT2
expression in renal biopsies from diabetic patients and that
inhibition prevented DN development in db/db mice, a
leptin-deficient type 2 diabetic model [81]. Furthermore, the
cardiovascular protection offered by these drugs has success-
fully translated into clinical studies, as noted by the EMPA-
REG OUTCOME trial [82]. Despite being prescribed for type
2 DM, SGLT2 inhibitors may afford further renoprotection to
younger type 1 DM patients, as demonstrated when
empagliflozin was added to insulin therapy [83]. The ability
of these drugs to target advanced kidney disease may, howev-
er, be questionable, as glucose-modulating effects lessened
with decreasing eGFR. As such, the dedicated renal trial,
CREDENCE [NCT02065791], should answer important
questions regarding the potential of SGLT2 inhibitors to treat
DN. Beyond SGLT2 inhibitors, clinical trials have suggested
that glucagon-like peptide-1 (GLP-1) receptor agonists and
dipeptidyl peptidase-4 (DPP-4) inhibitors can improve renal
function, possibly independent of their anti-glycaemic proper-
ties [84, 85]. These findings suggest that clinicians already
have access to a wealth of established drugs that could poten-
tially improve renal deterioration in DN patients.
Beyond the Limits of RAAS Inhibition
Under physiological conditions, two opposing arms of the
RAAS remain in relative equilibrium: the pressor arm
(ACE-I/angiotensin II) and the depressor arm (ACE-2/
Ang-(1–7)). There is increasing evidence that modulating
the counter regulatory depressor arm can attenuate kidney
damage. Chou et al. showed that hyperglycaemia lowered
ACE-2 levels in rat proximal tubular cells [86]. Additionally,
the positive effects of human recombinant ACE-2 in diabetic
Akita mice were demonstrated by Oudit et al. with attenuated
matrix expansion and blood pressure normalisation [87].
Moreover, whilst the Ang-(1–7) heptapeptide has been shown
to alter various disease indices, it is evident that its short half-
life will need to be improved to facilitate the development of
clinically relevant formulations [88, 89]. Despite the apparent
ceiling in terms of the RAAS, new developments suggest that
progress can still be made in improving the efficacy of
targeting this system in DN.
Oxidative Stress: Dampening the Destruction
Oxidative stress has emerged as an important novel target for
DN, as imbalanced redox signalling resulting from the exces-
sive generation of reactive oxygen species (ROS) exacerbates
renal injury. Unfortunately, non-selective inhibition of oxida-
tive stress has so far failed as a DN therapy, possibly due to
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unintentional interference with physiological ROS activity
and the increasingly apparent complexity of redox signalling.
More effective approaches may involve intensifying the ef-
fects of endogenous scavenging molecules, e.g. nuclear factor
erythroid 2-like 2 (Nrf2) [90]. The potential to target Nrf2 was
highlighted by Zheng et al. who showed that the Nrf2 ago-
nists, sulphoraphane and cinnamic aldehyde, reduced oxida-
tive stress and minimised pathological changes in the glomer-
uli of STZ-induced mice [91]. Clinical data from the BEAM
(Bardoxolone Methyl Treatment: Renal Function in CKD/
Type 2 Diabetes) trial supported the efficacy of Nrf2 activa-
tion, since bardoxylone methyl was associated with improved
renal function in patients with Type 2 DM [92]. The subse-
quent BEACON trial, however, was terminated prematurely
due to an increased risk of cardiovascular events [93]. Another
option to target this pathway may include the use of drugs
with known and well-characterised safety profiles, such as
the tetracycline antibiotic, minocycline, which stabilises
Nrf2 and decreases oxidative stress [94].
Selective targeting of NADPH oxidase (NOX) enzymes,
which are key modulators of the cellular redox state, may also
hold therapeutic potential in DN. For example, Gorin et al.
first showed that inhibiting NOX4, the most abundant renal
isoform, with anti-sense oligonucleotides reduced glomerular
expansion in diabetic rats [95]. Recent research also highlight-
ed the ability of a dual NOX1/NOX4 inhibitor, GKT137831,
to modulate renal pathology [96, 97]. Specifically, Gorin et al.
reported that GKT137831 suppressed diabetes-induced NOX
activity and superoxide generation whilst reducing mesangial
expansion in OVE26 mice [96]. More recently, Grey et al.
demonstrated that delayed intervention with GKT137831
could effectively downregulate pro-inflammatory pathways
in animal models with established DN [97]. Interestingly, ad-
ditional atheroprotection was observed with low doses but
was absent with higher concentrations of the drug.
Therefore, it seems that the effects of GKT137831 are both
dose- and tissue-dependent. Beyond this, a novel pan-NOX
inhibitor, APX-115, was shown to have similar or superior
efficacy to GKT137831 in DN [98]. This compound reduced
both plasma creatinine levels and urinary albumin excretion in
db/db obese/diabetic mice [98]. Taken together, whilst these
results appear promising, there remains a need to determine
whether or not these NOX inhibitors can improve patient end-
points in large, randomised DN clinical trials.
Inflammation: Calming the Storm
In light of the intrinsic link between inflammation and
hyperglycaemia, the ability to modulate key inflammatory
cascades appears attractive for DN therapy. For instance,
monocyte chemoattractant protein-1 (MCP-1) has emerged
as a potential therapeutic target. MCP-1-mediated macro-
phage accumulation was subsequently linked to progressive
functional deterioration [99]. Pre-clinical research has corre-
spondingly highlighted the potential benefits of MCP-1
targeting, showing that it reduced diabetic glomerulosclerosis
[100]. These positive effects were hinted at in a number of
clinical studies, which showed that two agents targeting the
MCP-1 axis, emapticap [101] and CCX140-B [102], de-
creased albuminuria levels in type 2 DM patients.
Conflicting evidence has also emerged with regard to anti-
inflammatory agents. Despite the central role of TGF-β in
propagating inflammatory renal damage, clinical trials of
TGF-β inhibitors reported underwhelming results. As such,
the promise of anti-TGF-β1 therapy failed to materialise when
a phase 2 study showed that there were no positive effects on
DN progression [103]. The multi-functional capabilities of
TGF-β are increasingly being unveiled. In this way, research
has challenged the previously well-accepted pathogenic role
of TGF-β by illustrating its potent anti-inflammatory [104]
and anti-apoptotic potential [105]. Significantly, a recent pa-
per published in JASN demonstrated that a dual specificity
anti-TGF-β antibody could reduce renal lesions when specif-
ically targeted to the extracellular matrix of the kidney [106].
The Tcell modulator, abatacept, which is currently licenced
for rheumatoid arthritis, failed to preserve renal function in
STZ-induced mice, as reflected by a failure to alter the albu-
min to creatinine ratio [107]. On the other hand, the potential
to repurpose an old drug for DN has proved promising with
regard to the methyxanthine derivative, pentoxifylline. The
ability of this approved claudication therapy to inhibit
TNF-α may have contributed to the promising results ob-
served during the PREDIAN trial, where pentoxifylline
caused significant reductions in urinary albumin excretion in
DN patients [108]. Taken together, these studies suggest that
specific elements of the immune system drive DN pathology
and as such, translational efforts will need to focus toward
their identification and targeting. It should also be noted that
albuminuria may not be the most appropriate surrogate marker
of efficacy for anti-inflammatory agents. As such, until novel
biomarkers can be identified, future research will need to con-
sider the evaluation of hard renal endpoints to monitor patient
response to therapy.
Renal Fibrosis: an Emerging Target
Beyond inflammation and oxidative stress, many groups have
proposed that targeting renal fibrosis may be an effective way
to further slow functional deterioration in DN. The TGF-β
inhibitor, pirfenidone, has shown anti-fibrotic and
renoprotective capabilities [109], but its use was associated
with gastrointestinal side effects [110]. Interestingly, a phase
I trial of anti-connective tissue growth factor (CTGF) mono-
clonal antibodies demonstrated an ability to decrease the urinary
albumin to creatinine ratio [111] but following the termination
of a phase II trial, it seems that this strategy is no longer being
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pursued. Of interest, the DPP-4 inhibitor, linagliptin, demon-
strated notable anti-fibrotic effects via the inhibition of
TGF-β2-induced EndoMT in a type 1 diabetic mouse model
[112]. Reductions in the levels of gremlin 1 (GREM1) have also
been shown to attenuate diabetic and other forms of renal fibro-
sis [113–115]. Other options to target renal fibrosis have recent-
ly included targeting homeodomain-interacting protein kinase 2
(HIPK2) [116] or SMAD7 gene transfer [117]. MicroRNA
modulation has shown significant promise, as the inhibition
of mir-192 successfully repressed renal fibrosis in DN [118].
Mir-103b inhibition also improved renal tubulointerstitial fibro-
sis by suppressing Snail-induced EMT [119]. Vitamin D defi-
ciency has been linked to an increased severity of structural
renal alterations [120]. In a study by Tian et al., administration
of active vitamin D attenuated renal fibrosis and protected renal
function [121], making this approach a potential future consid-
eration in the management of DN patients. Many of these ther-
apies remain in the pre-clinical phase, and their efficacy in
human patients has yet to be demonstrated.
Harnessing Cellular Defences
An alternative approach to DN treatment could revolve around
the use of agents to harness the body’s cytoprotective path-
ways. Thus, instead of blocking disease-driving molecules, it
may be more fruitful to focus on those agents that can mobilise
our innate molecular defences. Such approachesmay be able to
circumvent the damaging effects of glucotoxicity. One relevant
mechanism is the nutrient-sensitive process of autophagy,
which is downregulated in DN [122]. Autophagy is a tightly
regulated lysosomal process that results in the degradation of
unwanted cytoplasmic constituents [123] and is thus responsi-
ble for maintaining intra-cellular homeostasis. Moreover, au-
tophagy is activated in response to cellular stresses, including
nutrient deprivation, oxidative stress and metabolic abnormal-
ities. Evidence suggests that in DN, autophagic systems be-
come insufficient and that deficient autophagy has the potential
to accelerate renal fibrosis [124]. Importantly, key features of
DN were recapitulated in animal models via enhanced activa-
tion of the autophagy-inhibiting gene, mechanistic target of
rapamycin kinase (mTOR) [125]. Moreover, levels of the mi-
tochondrial protector, sirtuin 1, were significantly reduced in
the diabetic kidney [126].
Considering the proposed importance of autophagy in the
maintenance of renal homeostasis, the complexities of this
mechanism remain incompletely understood. Whilst this pro-
cess is impaired in both constituent cells of the glomeruli and
the renal tubules, its impact on podocyte destruction is partic-
ularly interesting. Podocytes are terminally differentiated epi-
thelial cells, which form an important layer in the molecular
sieve of the glomerular basement membrane. Their role in DN
pathogenesis was confirmed in a landmark publication by
Pagtalunan et al., which showed that a reduction in podocyte
number was positively associated with albuminuria [127].
Given their inability to repair following damage, these cells
demonstrate high basal autophagic activity under physiologi-
cal conditions. A more recent study reported that podocyte-
specific autophagy-deficient diabetic mice developed signifi-
cant proteinuria, whilst also confirming the lack of autophagy
in renal biopsy tissue, which displayed intra-cellular accumu-
lation of p62, a specific autophagy target [128]. Furthermore,
another group demonstrated that hyperglycaemia-induced
overexpression of the permeability-inducing molecule vascu-
lar endothelial growth factor (VEGF) could be enhanced by
the autophagy inhibitor, 3-methyladenine [129]. These find-
ings were in line with previous research demonstrating that
this autophagy-driven phenomenon was sensitive to changing
levels of ROS [129]. However, caution must be exercised
when interpreting and undertaking autophagy-focused studies
so as to avoid the extrapolation of findings regarding the
amount of autophagy-produced substrates to variations in au-
tophagy instability among cells.
As such, the ability to modulate autophagy may provide an
exciting mechanism to reverse DN pathology. Indeed, calorie
restriction in diabetic rats proved to regulate disordered au-
tophagy by upregulating sirtuin 1 [130] and by suppressing
mTOR [131]. Given the widely accepted health-prolonging
benefits of calorie restriction, the adherence of patients to in-
tense dietary modifications may be a useful additive approach.
However, the degree of calorie restriction remains poorly de-
fined and implementation of such radical health behaviours
may ultimately be difficult to implement. Alternatively, using
compounds to modulate these nutrient-sensitive pathways
may be a more feasible strategy. Such agents could include
the anti-diabetic drug metformin [132] or the herbal com-
pound paeoniflorin [133]. In particular, modulating the ex-
pression of AMP-activated protein kinase (AMPK), an au-
tophagy activator and target of metformin, has proven worth-
while. Kim et al. found that phosphorylation of AMPK by
resveratrol prevented renal lipotoxicity and glucotoxicity
[134]. In addition, Lee et al. demonstrated that pharmacolog-
ical activation of AMPK successfully attenuated renal hyper-
trophy in diabetic rats [135]. Moreover, the macrolide com-
pound, rapamycin, has proven capable of inhibiting the
mTORC1 pathway and its potent ability to modulate DN pa-
thology was demonstrated in various animal models [136,
137]. To date, the potential targeting of this intricate cellular
defence mechanism appears promising. However, this thera-
peutic strategy is still in its infancy and as such, further re-
search is required to inform more sophisticated approaches to
reactivate autophagy.
Stem Cells: the Emerging Frontier
Recent years have seen increasing attempts to move the field
of stem cell biology into the clinical environment. However,
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the strategies taken to harness the therapeutic potential of stem
cells have proven to be challenging. Whilst the clinical use of
embryonic stem cells is hampered by a string of ethical con-
cerns, the emergence of induced pluripotent stem cells (iPSCs)
has provided an attractive alternative. A number of groups
have reported the generation of renal subtypes from iPSCs
[138–140]. For example, Lam et al. produced cells character-
istic of intermediate mesoderm, which subsequently
expressed characteristic proximal tubular markers [140]. It
should, however, be pointed out that iPSC-derived popula-
tions display significant phenotypic variability. Beyond the
difficulties of generating pure cell populations, methods for
renal lineage differentiation require additional optimisation in
order to produce the high-quality cell yield needed for thera-
peutic purposes.
Considering that the kidney is essentially a mesodermal
organ, focus has understandably shifted to mesenchymal stem
cells (MSCs), which are multi-potent bone marrow-derived
cells and connective tissue progenitors. Interestingly, Wang
et al. showed that intra-arterial administration ofMSCs to type
1 diabetic Sprague Dawley rats reduced podocyte effacement
and prevented the loss of glomerular nephrin and podocin
[141]. Whilst this treatment did not alter blood glucose levels,
Ezquer et al. reported that MSC-treated diabetic mice demon-
strated improved glycaemic levels within 1 week and that
remarkably, euglycaemia was achieved within 1 month post-
treatment [142].
As well as their regenerative ability, MSCs possess potent
immunomodulatory functions and are capable of secreting
various signalling molecules by which, among other actions,
they are able to antagonise TGF-β signalling [143]. Indeed,
these cells are known to exert many of their effects through
paracrine signalling. Moreover, exosomes contained in MSC-
conditioned media were recently shown to be key orchestra-
tors of their therapeutic actions [144]. Taken together, it is
evident that MSCs hold significant therapeutic potential; the
ongoing EU-funded NEPHSTROM trial [NCT02585622]
will provide essential safety information for allogenic bone
marrow-derived MSC treatment in DN patients.
Conclusions and Perspectives
DN is a serious complication that develops in approximately
one third of diabetic patients. Unfortunately, despite the obvi-
ous benefits derived from managing hyperglycaemia and hae-
modynamic dysregulation, many patients progress to ESRD
requiring dialysis or transplant. Although there are continued
advancements in the field, the underlying molecular mecha-
nisms of DN have yet to be completely elucidated. Even
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though hyperglycaemia-induced TGF-β upregulation has
emerged as a central pathogenic mechanism in DN, research
has highlighted the contributions of additional pleiotropic cel-
lular events. These changes are set against the background of a
multi-layered cellular communication system within the kid-
ney. It has therefore been proposed that DN cannot be consid-
ered as a simple ‘microvascular’ disease. Future efforts to
refine our understanding of DN pathophysiology will be nec-
essary to resolve the current debates, determine the relative
importance of newly identified pathogenic mechanisms and
prioritise novel therapeutic targets.
Whilst the complex nature of DN is likely responsible for
many of the obstacles that are preventing the successful trans-
lation of novel targets into effective DN therapeutics, this com-
plexity has provided researchers with a wealth of pathways
available for potential targeting (Fig. 2). Such research should
aid in the translation of new DN-targeted therapies that will
improve patient outcomes. Oxidative stress, inflammation and
fibrosis are pivotal interlocking pathogenic processes that con-
tribute to DN. As such, the ability to target each of these dele-
terious mechanisms presents an exciting therapeutic avenue.
Despite appearing as obvious targets, modulation of these path-
ways has not been straightforward. Novel approaches, includ-
ing cellular therapies or the modulation of autophagy, may
eventually revolutionise DN treatment. Nevertheless, many
challenges remain for researchers in the field of DN. These
range from the use of unrepresentative animal models to poorly
defined clinical trial inclusion criteria, which make it almost
impossible to confirm causality. Additionally, the ability to
measure traditional renal endpoints necessitates the use of re-
source-intensive, long-lasting clinical trials. In this regard,
multi-level ‘omics’ studies may help to identify appropriate
DN biomarkers. Improved design and execution of clinical
trials for DN are urgently needed. Drug safety is another major
concern, as the suboptimal compensatory mechanisms in DN
patients make them particularly vulnerable to adverse drug ef-
fects. Moreover, the need to foresee potential drug interactions
will be an important step to improving patient outcomes.
Further to cutting-edge developments in genomic technol-
ogy, research has pinpointed several key pathways related to
DN initiation and progression. The true challenge, however,
will be to overcome the inherent heterogeneity of DN to iden-
tify novel drug targets that are relevant to large patient num-
bers. In essence, the successful management of DN will hinge
on the implementation of a multi-disciplinary, multi-target ap-
proach, in which novel therapeutics are coupled with the tra-
ditional management strategies of promoting glucose control,
blood pressure management and continued engagement in all-
round positive health behaviours. Such complexity dictates
that one treatment for DN will not cure all, so more
personalised approaches will be required. In essence, it is only
with this realisation in mind that medical professionals will be
best equipped to manage the DN patient population.
Continued investment in basic and clinical researches will be
essential to successfully translate exciting pre-clinical data
into reliable biomarkers and effective therapeutics for DN.
Such work holds the potential to bring about measurable
changes in clinical outcomes and to establish an improved
quality and quantity of life for the DN patient population.
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